Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder

Urology

Volumn 55, Issue 2, 2000, Pages 223-226

  Mian, Christine ^a   Lodde, Michele ^b   Haitel, Andrea ^b   Vigl, Eduard Egarter ^a   Marberger, Michael ^b   Pycha, Armin ^b  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; CYTOKERATIN 18; NUCLEAR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FROZEN SECTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KERATINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0033964886     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00383-0     Document Type: Article

References (18)

1. Wiener H.G., Mian C., Haitel A., et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol. 159:1998;1876-1880.
2. Chopin D.K., Laurent J.C. Monoclonal antibodies in bladder cancer cytology. World J Urol. 9:1993;75-78.
3. Fradet Y., Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol. 11:1993;145-153.
4. Soloway M.S., Briggman J.V., Carpinito G.A., et al. Use of a new marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 156:1996;363-367.
5. Sarosdy M.F., Hudson M.A., Ellis W.J., et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 50:1997;349-353.
6. Leyh H, Marberger M, Pagano P, et al: Results of a European multicenter trial comparing the BTA stat-test to urine cytology in patients suspected of having bladder cancer (abstract). J Urol 157: 336, 1997.
7. Ishak LM, Enfield DL, Sarosdy MF, and the Multicenter Group: Detection of recurrent bladder cancer using a new quantitative assay for bladder tumor (abstract). J Urol 157: 337, 1997.
8. Sobin LH, and Wittekind C: UICC TNM Classification of Malignant Tumours, 5th ed. New York, Wiley Liss, 1997, pp 187-190.
9. Sanchez-Carbayo M., Herrero E., Megias J., et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer test as a tumor marker for transitional cell carcinoma of the bladder. J Urol. 161:1999;1110-1115.
10. Banks R.E., Porter W.H., Whelan P., et al. Soluble forms of the adhesion E-cadherin molecule in urine. J Clin Pathol. 48:1995;179-180.
11. Klein A, Zemer R, Buchumensky V, et al: Detection of bladder carcinoma: a urine test, based on cytokeratin expression (abstract). J Urol 157: 339, 1997.
12. Kavaler E, Shu WP, Chang Y, et al: Detection of human bladder cancer cells in voided urine samples by assaying the presence of telomerase activity (abstract). J Urol 157: 338, 1997.
13. Fraser R.A., Ravry M.J., Segura J.W., et al. Clinical evaluation of urinary and serum embryogenic antigen in bladder cancer. J Urol. 114:1975;226-229.
14. Myanaga N., Akaza H., Ishikawa S., et al. Clinical evaluation of nuclear matrix protein (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol. 31:1997;163-168.
15. Witjes J.A., van der Poel H.G., van Balken M.R., et al. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol. 33:1998;387-391.
16. Moll R., Achtstätter T., Becht E., et al. Cytokeratins in normal and malignant epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines. Am J Pathol. 132:1988;123-144.
17. Rodriguez-Villanueva J, Dinney CPN, Grossmann HB, et al: Evaluation of the NMP22 immunoassay in the detection of transitional cell carcinoma (UCC) of the urinary tract (abstract). J Urol 157: 336, 1997.
18. Sanchez-Carbayo M., Megias J., Herrero E., et al. Comparative role of urinary NMP22, CYFRA 21-1, UBC quantitative, UBC qualitative and TPA in the diagnosis of bladder cancer. Eur Urol. 35:(suppl 2):1999;131.